Please use this identifier to cite or link to this item:
|Title:||Comparative in vitro and in vivo antimalarial activity of the indole alkaloids ellipticine, olivacine, cryptolepine and a synthetic cryptolepine analog|
|Authors:||Silva, Luiz Francisco Rocha e|
Amorim, Rodrigo C.N.
Melo, Márcia R.S.
Henrique, Marycleuma Campos
Nunomura, Sergio Massayoshi
Costa, Mônica Regina Farias
Andrade Neto, Valter Ferreira de
Costa, David Siqueira
Dantas, Glucia L.S.
Moreira, Rui R.N.
Pinto, A. C.
Tadei, Wanderli Pedro
Zacardi, R. S.
Eberlin, M. N.
Pohlit, Adrian Martin
In Vitro Study
In Vivo Study
Mice, Inbred Strains
|metadata.dc.relation.ispartof:||Volume 20, Número 1, Pags. 71-76|
|Abstract:||Indole alkaloids ellipticine (1), cryptolepine triflate (2a), rationally designed 11-(4-piperidinamino)cryptolepine hydrogen dichloride (2b) and olivacine (3) (an isomer of 1) were evaluated in vitro against Plasmodium falciparum and in vivo in Plasmodium berghei-infected mice. 1-3 inhibited P. falciparum (IC50 ≤ 1.4 μM, order of activity: 2b > 1 > 2a > 3). In vitro toxicity to murine macrophages was evaluated and revealed selectivity indices (SI) of 10-12 for 2a and SI > 2.8 × 102 for 1, 2b and 3. 1 administered orally at 50 mg/kg/day was highly active against P. berghei (in vivo inhibition compared to untreated control (IVI) = 100%, mean survival time (MST) > 40 days, comparable activity to chloroquine control). 1 administered orally and subcutaneously was active at 10 mg/kg/day (IVI = 70-77%; MST = 27-29 days). 3 exhibited high oral activity at ≥50 mg/kg/day (IVI = 90-97%, MST = 23-27 days). Cryptolepine (2a) administered orally and subcutaneously exhibited moderate activity at 50 mg/kg/day (IVI = 43-63%, MST = 24-25 days). At 50 mg/kg/day, 2b administered subcutaneously was lethal to infected mice (MST = 3 days) and moderately active when administered orally (IVI = 45-55%, MST = 25 days). 1 and 3 are promising compounds for development of antimalarials. © 2012 Elsevier GmbH.|
|Appears in Collections:||Artigos|
This item is licensed under a Creative Commons License